MedPath

Effetivity of Dutasteride and Aloe Vera Extract Combination on Angiogenesis and Obstruction on Benign Prostatic Hyperplasia

Not Applicable
Recruiting
Conditions
BPH (Benign Prostatic Hyperplasia)
Interventions
Drug: Aloevera + dutasteride
Registration Number
NCT07065682
Lead Sponsor
Universitas Diponegoro
Brief Summary

This study is a double blinded RCT with pre-post test design on the effect of combination of dutasteride and aloe vera, compared to dutasteride only, on uroflowmetry results, prostate volume, and VEGF serum level among patients with benign prostate hyperplasia. The treatment was given for 12 weeks

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Male
Target Recruitment
84
Inclusion Criteria
  • Diagnosed with BPH clinically or radiologically (prostate volume > 30 gram, Qmax <15 mL/s)
  • Willing to participate to the study
Exclusion Criteria
  • Clinically or radiologically suspected of having prostatic cancer
  • Previous prostatic surgery
  • Patients with urinary retention
  • Patients with BPH complications: urinary tract infections, urolithiasis, or hydroneprhosis
  • Previously consumed alpha blocker or 5ARI in the last 6 months
  • Have consumed aloe vera extract routinely

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Dutasteride 0,5 mg/day + Aloe Vera Extract 380 mg/dayAloevera + dutasteride-
DutasterideDutasteride (0.5mg)Control
Primary Outcome Measures
NameTimeMethod
Uroflowmetry result12 weeks

Qmax of Uroflowmetry result

Secondary Outcome Measures
NameTimeMethod
Prostatic volume12 weeks

Measured by transabdominal ultrasonography

VEGF12 weeks

serum VEGF level

Trial Locations

Locations (1)

RSUD Karawang

🇮🇩

Karawang, West Java, Indonesia

RSUD Karawang
🇮🇩Karawang, West Java, Indonesia
Achmad Rizky Herda Pratama dr. Achmad Rizky Herda Pratama, Sp.U, S.H, Urologist
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.